1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
International Research in Infectious Diseases (R01 Clinical Trial Not Allowed) is a grant from the National Institutes of Health (NIH) that funds high-priority infectious disease research by international investigators in resource-constrained countries. The program supports regionally relevant research addressing infectious diseases of significant public health importance in low- and middle-income countries.
Organizations in low- and lower-middle-income economies by World Bank classification are particularly encouraged. Awards range from $125,000 to $500,000. Eligible applicants are non-domestic organizations headquartered in resource-constrained countries as classified by the World Bank.
Get alerted about grants like this
Save a search for “National Institutes of Health (NIH)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
International Research in Infectious Diseases (R01 Clinical Trial Not Allowed) | Research Funding National Institutes of Health International Research in Infectious Diseases (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to support applications for high-priority, regionally relevant infectious diseases research by international investigators in resource-constrained countries.
Applicant organizations must be headquartered in foreign (non-U.S.) resource-constrained countries (i.e. low-income economies, lower-middle-income economies, and upper-middle-income economies by World Bank Classification ). Applicant organizations headquartered in low- and lower-middle income economy countries are particularly encouraged to apply.
Eligibility status of applicant organizations will be determined by the World Bank Classification list at the time of application submission. Letter of Intent Due Date: 30 days prior to Application Due Date.
Application Due Dates: August 2, 2023; August 2, 2024; AIDS Application Due Dates: August 2, 2023; August 2, 2024; RFA-AI-23-023 Expiration Date: New Date May 24, 2025 per NOT-OD-25-113 (Originally August 02, 2025 ) Applicant organizations must be headquartered in foreign (non-U.S.) resource-constrained (i.e. low-income economies, lower-middle-income economies, and upper-middle-income economies) by World Bank Classification at the time of application submission.
Applicant organizations headquartered in low- and lower-middle income economy countries are particularly encouraged to apply. PDs/PIs must have a primary appointment at an institution/organization in an eligible country. Investigators who currently serve or have served as PDs/PIs on R01-equivalent grants (other than an expiring/current IRID) or contracts funded by NIH are not eligible to apply.
For institutions/organizations proposing multiple PDs/PIs, all PDs/PIs must have primary appointment at an institution/organization in an eligible country. Application budgets should not exceed $125,000 in direct costs per year, and should reflect the actual needs of the project. The scope of the proposed project should determine the project period.
The maximum project period is 5 years. International Opportunities Medical - Clinical Science
Based on current listing details, eligibility includes: Non-domestic entities (foreign organizations); non-domestic entities (foreign institutions); and others Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates $125,000 - $500,000 Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Science Education Partnership Award (SEPA) is sponsored by National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH). The Science Education Partnership Award (SEPA) Program funds grants for innovative educational programs that create partnerships among biomedical and clinical researchers and K-12 teachers and schools, museums and science centers, media experts, and other educational organizations. The program aims to improve STEM literacy through innovative P-12 and informal science education. Projects can be classroom-based or informal science education projects in venues such as science centers, museums, and libraries.
Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required) is sponsored by National Institutes of Health (NIH). This K23 award supports individuals with a clinical doctoral degree who propose to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development in patient-oriented research.
Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional) is sponsored by National Institute of Mental Health (NIMH), National Institutes of Health (NIH). This funding opportunity is a companion to the R21 mechanism and also aims to stimulate research to understand the link between social disconnection and suicidal thoughts and behaviors in late life. It focuses on identifying mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. This R01 mechanism is appropriate for applications with preliminary data.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.